GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CASI Pharmaceuticals Inc (FRA:ENM) » Definitions » Cyclically Adjusted PS Ratio

CASI Pharmaceuticals (FRA:ENM) Cyclically Adjusted PS Ratio : 1.97 (As of Jun. 10, 2024)


View and export this data going back to 2007. Start your Free Trial

What is CASI Pharmaceuticals Cyclically Adjusted PS Ratio?

As of today (2024-06-10), CASI Pharmaceuticals's current share price is €1.54. CASI Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €0.78. CASI Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 1.97.

The historical rank and industry rank for CASI Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:ENM' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.76   Med: 3.27   Max: 25.59
Current: 1.89

During the past years, CASI Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 25.59. The lowest was 0.76. And the median was 3.27.

FRA:ENM's Cyclically Adjusted PS Ratio is ranked better than
75.79% of 504 companies
in the Biotechnology industry
Industry Median: 5.47 vs FRA:ENM: 1.89

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

CASI Pharmaceuticals's adjusted revenue per share data for the three months ended in Mar. 2024 was €0.234. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €0.78 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


CASI Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for CASI Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CASI Pharmaceuticals Cyclically Adjusted PS Ratio Chart

CASI Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.31 21.68 6.34 1.04 3.83

CASI Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.32 1.38 1.37 3.83 1.96

Competitive Comparison of CASI Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, CASI Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CASI Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where CASI Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



CASI Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

CASI Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1.54/0.78
=1.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CASI Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, CASI Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.234/115.2271*115.2271
=0.234

Current CPI (Mar. 2024) = 115.2271.

CASI Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 98.200 0.000
201409 0.000 98.900 0.000
201412 0.006 99.000 0.007
201503 0.007 99.900 0.008
201506 0.006 99.500 0.007
201509 0.000 100.500 0.000
201512 0.000 100.600 0.000
201603 0.000 102.200 0.000
201606 0.000 101.400 0.000
201609 0.000 102.400 0.000
201612 0.000 102.600 0.000
201703 0.000 103.200 0.000
201706 0.000 103.100 0.000
201709 0.000 104.100 0.000
201712 0.000 104.500 0.000
201803 0.000 105.300 0.000
201806 0.000 104.900 0.000
201809 0.000 106.600 0.000
201812 0.000 106.500 0.000
201903 0.000 107.700 0.000
201906 0.000 107.700 0.000
201909 0.264 109.800 0.277
201912 0.125 111.200 0.130
202003 0.312 112.300 0.320
202006 0.235 110.400 0.245
202009 0.305 111.700 0.315
202012 0.320 111.500 0.331
202103 0.386 112.662 0.395
202106 0.425 111.769 0.438
202109 0.493 112.215 0.506
202112 0.580 113.108 0.591
202203 0.596 114.335 0.601
202206 0.596 114.558 0.599
202209 0.758 115.339 0.757
202212 1.060 115.116 1.061
202303 0.584 115.116 0.585
202306 0.679 114.558 0.683
202309 0.619 115.339 0.618
202312 0.471 114.781 0.473
202403 0.234 115.227 0.234

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CASI Pharmaceuticals  (FRA:ENM) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


CASI Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of CASI Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CASI Pharmaceuticals (FRA:ENM) Business Description

Traded in Other Exchanges
Address
9620 Medical Center Drive, Suite 300, Rockville, MD, USA, 20850
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.

CASI Pharmaceuticals (FRA:ENM) Headlines

No Headlines